Recent advances in understanding the pathogenesis of scleroderma- interstitial lung disease

45Citations
Citations of this article
75Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Systemic sclerosis (scleroderma, SSc) is a heterogeneous autoimmune connective tissue disease of unknown etiology. Interstitial lung disease (ILD) is a frequent complication, and a significant contributor to morbidity and mortality among SSc patients. SSc-ILD most commonly occurs within 10 years of diagnosis, and may be seen in patients with either the limited or diffuse cutaneous subset of SSc. SSc-ILD is a multifaceted disease process in which different factors and pathways are involved. Aberrant function of a variety of lung cells, cytokines, growth factors, peptides, and bioactive proteins, in combination with genetic and epigenetic regulators, have crucial functions in the pathogenesis of this disease. Here we present our view on recent advances regarding the pathogenesis of SSc-ILD. © 2014 Springer Science+Business Media New York.

Cite

CITATION STYLE

APA

Akter, T., Silver, R. M., & Bogatkevich, G. S. (2014). Recent advances in understanding the pathogenesis of scleroderma- interstitial lung disease. Current Rheumatology Reports, 16(4). https://doi.org/10.1007/s11926-014-0411-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free